Targeting gut microbiota as a possible therapy for diabetes
- PMID: 25818484
- DOI: 10.1016/j.nutres.2015.03.002
Targeting gut microbiota as a possible therapy for diabetes
Abstract
The incidence of diabetes has increased rapidly across the entire world in the last 2 decades. Accumulating evidence suggests that gut microbiota contribute to the pathogenesis of diabetes. Several studies have demonstrated that patients with diabetes are characterized by a moderate degree of gut microbial dysbiosis. However, there are still substantial controversies regarding altered composition of the gut microbiota and the underlying mechanisms by which gut microbiota interact with the body's metabolism. The purpose of this review is to define the association between gut microbiota and diabetes. In doing so an electronic search of studies published in English from January 2004 to the November 2014 in the National Library of Medicine, including the original studies that addressed the effects of gut microbiota on diabetes, energy metabolism, inflammation, the immune system, gut permeability and insulin resistance, was performed. Herein, we discuss the possible mechanisms by which the gut microbiota are involved in the development of diabetes, including energy metabolism, inflammation, the innate immune system, and the bowel function of the intestinal barrier. The compositional changes in the gut microbiota in type 2 and type 1 diabetes are also discussed. Moreover, we introduce the new findings of fecal transplantation, and use of probiotics and prebiotics as new treatment strategies for diabetes. Future research should be focused on defining the primary species of the gut microbiota and their exact roles in diabetes, potentially increasing the possibility of fecal transplants as a therapeutic strategy for diabetes.
Keywords: Diabetes; Fecal transplant; Gut microbiota; Inflammation; Metabolism.
Copyright © 2015 Elsevier Inc. All rights reserved.
Similar articles
-
[Physiological patterns of intestinal microbiota. The role of dysbacteriosis in obesity, insulin resistance, diabetes and metabolic syndrome].Orv Hetil. 2016 Jan 3;157(1):13-22. doi: 10.1556/650.2015.30296. Orv Hetil. 2016. PMID: 26708682 Review. Hungarian.
-
Gut microbiota interactions with obesity, insulin resistance and type 2 diabetes: did gut microbiote co-evolve with insulin resistance?Curr Opin Clin Nutr Metab Care. 2011 Sep;14(5):483-90. doi: 10.1097/MCO.0b013e328348c06d. Curr Opin Clin Nutr Metab Care. 2011. PMID: 21681087 Review.
-
Therapeutic interventions for gut dysbiosis and related disorders in the elderly: antibiotics, probiotics or faecal microbiota transplantation?Benef Microbes. 2017 Apr 26;8(2):179-192. doi: 10.3920/BM2016.0115. Epub 2016 Dec 23. Benef Microbes. 2017. PMID: 28008784 Review.
-
Gut microbiota and type 2 diabetes mellitus.Endocrinol Nutr. 2016 Dec;63(10):560-568. doi: 10.1016/j.endonu.2016.07.008. Epub 2016 Sep 12. Endocrinol Nutr. 2016. PMID: 27633134 Review. English, Spanish.
-
The intricate association between gut microbiota and development of type 1, type 2 and type 3 diabetes.Expert Rev Clin Immunol. 2013 Nov;9(11):1031-41. doi: 10.1586/1744666X.2013.848793. Epub 2013 Oct 21. Expert Rev Clin Immunol. 2013. PMID: 24138599 Review.
Cited by
-
Gut Microbiota and Antidiabetic Drugs: Perspectives of Personalized Treatment in Type 2 Diabetes Mellitus.Front Cell Infect Microbiol. 2022 May 31;12:853771. doi: 10.3389/fcimb.2022.853771. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 35711668 Free PMC article. Review.
-
The Immunomodulatory Effect of the Gut Microbiota in Kidney Disease.J Immunol Res. 2021 May 15;2021:5516035. doi: 10.1155/2021/5516035. eCollection 2021. J Immunol Res. 2021. PMID: 34095319 Free PMC article. Review.
-
Antibacterial and Antiviral Properties of Tetrahydrocurcumin-Based Formulations: An Overview of Their Metabolism in Different Microbiotic Compartments.Life (Basel). 2022 Oct 26;12(11):1708. doi: 10.3390/life12111708. Life (Basel). 2022. PMID: 36362863 Free PMC article. Review.
-
Gut microbiota and its metabolites - molecular mechanisms and management strategies in diabetic kidney disease.Front Immunol. 2023 Jan 19;14:1124704. doi: 10.3389/fimmu.2023.1124704. eCollection 2023. Front Immunol. 2023. PMID: 36742307 Free PMC article. Review.
-
Targeting gut microbiota as a possible therapy for mastitis.Eur J Clin Microbiol Infect Dis. 2019 Aug;38(8):1409-1423. doi: 10.1007/s10096-019-03549-4. Epub 2019 May 11. Eur J Clin Microbiol Infect Dis. 2019. PMID: 31079312 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical